Protagonist grabs $4M in VC cash from Russia's Pharmstandard; Integrated Diagnostics' spinoff gains seed money;

@FierceBiotech: ICYMI Friday: San Diego biotech insider accused of shooting RNAi expert and brother-in-law. Article | Follow @FierceBiotech

@JohnCFierce: Perlmutter has been working hard to create a new narrative for R&D. More efficient, smarter, focused on winners. Legacy bites again. | Follow @JohnCFierce

@EmilyMFierce: NIH launches $45M Alzheimer's research effort, awards funds to 3 preclinical studies. Story from FierceBiotech Research | Follow @EmilyMFierce

> Menlo Park, CA-based Protagonist Therapeutics has tacked $4 million onto its Series B, bringing the total to $18 million. Russia's Pharmstandard added the new money. Release

> Seattle's Integrated Diagnostics has decided to spin out a new company called InDi Molecular with $1.5 million in seed cash from InterWest Partners. Story

> Declining M&A deal values and fewer PMA approvals slammed the med tech industry in the first 6 months of 2013. But the global medical device and diagnostics market will have grown 4.5% annually from 2012 through 2018 to be worth a massive $455 billion at the end of that period, a new report predicted. Report

Medical Device News

@FierceMedDev: Veracyte, a molecular diagnostic company, has filed plans for an IPO. Story | Follow @FierceMedDev

@DamianFierce: FDA device chief Jeffrey Shuren blogs about "landmark" UDI rule. More | Follow @DamianFierce

@MarkHFierce: RainDance, a maker of gene-sequencing tools, raised up to $35M in debt financing to keep the sales push going. Article | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Bind collects $70.5M IPO to support Accurin tech. More from FierceDrugDelivery | Follow @MichaelGFierce

> SafeShot pulls in $9M to develop better pre-filled syringes. More

> AdvaMed: Medical device prices have plunged. News

> Report: Med tech industry on growth track despite obstacles. Item

Pharma News

@FiercePharma: Big Pharma pressures U.K. officials on cancer drug use as special fund set to expire. More from PMLiVE | Follow @FiercePharma

@EricPFierce: market is growing rapidly but so is the number of drugs approved to treat it. Novartis gets in. Story | Follow @EricPFierce

> Who are the richest biopharma execs? Not all the usual suspects. Report

> Novartis board to shrink executive pay, director says. More

CRO News

> Quintiles seals deal for Novella. News

> PPD lures UCB exec to head immunology. Report

> Capsugel expands in U.S., Europe. Item

> CMO Aesica puts up $48M to make diabetes drugs. Article

> Catalent lands manufacturing deal with Supernus. More

> InVentiv partners up for policy, site selection. Story

Biotech IT News

> BRAIN Initiative prioritizes better data storage and analysis. More

> Biotech broker fined $5,000 for venting on Facebook. Item

> FDA posts final guidance on electronic source data. Story

> Google hires ex-Genentech CEO to lead ambitious bio spinoff. Report

> Bioinformatics-driven Eisai subsidiary inks discovery alliance. News

> New York Genome Center opens $54M biomedical-research hub. Article

Suggested Articles

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.

Fresh off Tilos Therapeutics’ $773 million sale to Merck, Barbara Fox is taking the helm of another Cambridge-based company: Rheos Medicines.

The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.